tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Jonathan Demchick, 4 are a HOLD (36.36%), 4 are a BUY (36.36%), 3 are a SELL (27.27%).
Analyst Jonathan Demchick, carries an average stock price target met ratio of 87.5% that have a potential upside of 11.57% achieved within 318 days. Previously, Jonathan Demchick worked at MORGAN STANLEY.
Jonathan Demchick’s has documented 24 price targets and ratings displayed on 5 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on NUVA, NuVasive at 23-Feb-2023.
Analyst best performing recommendations are on GMED (GLOBUS MEDICAL).
The best stock recommendation documented was for GMED (GLOBUS MEDICAL) at 1/2/2018. The price target of $48 was fulfilled within 45 days with a profit of $4.83 (11.19%) receiving and performance score of 2.49.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 06-Apr-2020
$99
$24.35 (32.62%)
$103
2 months 6 days ago
(07-Aug-2026)
9/12 (75%)
$16.65 (20.22%)
210
Hold Since 28-Jul-2026
$82
$7.35 (9.85%)
$120
2 months 15 days ago
(28-Jul-2026)
9/16 (56.25%)
$1.42 (1.76%)
366
Buy Since 18-Nov-2025
$100
$25.35 (33.96%)
$115
2 months 27 days ago
(16-Jul-2026)
34/37 (91.89%)
$19.09 (23.59%)
357
Buy Since 09-Dec-2021
$115
$40.35 (54.05%)
$120
3 months ago
(13-Jul-2026)
10/14 (71.43%)
$35.25 (44.20%)
111
Hold Since 08-May-2026
$80
$5.35 (7.17%)
3 months 5 days ago
(08-Jul-2026)
2/2 (100%)
$3.8 (4.99%)
9
